ERG (ETS Transcription Factor ERG)

Furthermore, serum Phi combined with urinary PCA3-T2:ERG outperformed urinary PCA3-T2:ERG in each of the 3 algorithms reflecting different potential clinical workflows: (1) serum Phi and urine PCA3-T2:ERG tested simultaneously, either exceeding its own threshold (P = .04); (2) urine PCA3-T2:ERG first and those in the grey zone resolved by subsequent serum Phi (P = .03); and (3) serum Phi first and those in the grey zone resolved by subsequent urine PCA3-T2:ERG (P = .002). Combining serum Phi with urinary PCA3 RNA alone or together with urinary T2:ERG RNA, simultaneously or sequentially, improves selection of men for initial prostate biopsy and represents an avenue to improve early detection of aggressive PCa.

Virtual mIHC conducted on the same tissue section also allowed the identification and localization of small vessel invasion. This virtual mIHC approach can substantially improve diagnostic accuracy and efficiency in the histopathological evaluation of vascular invasion, potentially eliminating the need for traditional staining protocols and mitigating issues related to tissue loss and heterogeneity.

The t(16;21)(p11;q22) FUS::ERG fusion gene is rare in pediatric AML and associated with poor prognosis. Allo-HSCT may mitigate the adverse prognostic impact of the FUS::ERG fusion gene and contribute to prolonged survival.

WWOX2 serves as a tumor suppressor, whereas FUT1 functions as a promoter of malignancy. The interplay between tumor inducers and suppressors may serve as a survival mechanism for cancer cells, a subject that has received limited research attention.

P1, N=50, Not yet recruiting, Amgen | Trial completion date: Jul 2029 --> Apr 2030 | Trial primary completion date: Jul 2029 --> Apr 2030

PARP inhibition with olaparib increased residual γH2AX/53BP1 foci post-irradiation in ERG+ cells, indicating enhanced radiosensitization...These findings suggest that ERG expression promotes dependency on PARP1-EJ, rendering ERG+ PCa more susceptible to PARP inhibition. Combining PARP inhibitors with RT may offer a tumor-selective radiosensitization for ERG+ PCa patients.

Certain immunohistochemical, radiological, and molecular parameters may be predictive of pathological upgrading in GG1 prostate cancer. Incorporation of these biomarkers into diagnostic evaluation and treatment planning may aid in refining risk stratification and avoiding overtreatment in clinically indolent cases. Although ADCtumor values were significantly associated with upgrading, their correlation with molecular markers such as PTEN, ERG, Ki-67, and TMPRSS2-ERG fusion were not statistically significant.

The TMPRSS2 rs12329760 T allele is associated with elevated prostate cancer risk and more severe clinicopathological features in Moroccan men. These findings highlight the potential prognostic relevance of the V160M variant and emphasize the need for further cellular and molecular studies to elucidate its functional role in AR signaling, TMPRSS2-ERG fusion biology, and ERG-related tumor aggressiveness. Such insights may contribute to the development of risk-stratified PCa management and tailored active surveillance strategies.

Primary splenic angiosarcoma rarely presents with non-nodular intrasinusoidal hepatic metastasis, mimicking infiltrative liver diseases. Liver biopsy may fail to yield a definitive diagnosis. Therefore, a splenectomy may be required to establish a definitive diagnosis and guiding appropriate management when liver biopsy is inconclusive. Recognizing this uncommon metastatic pattern is crucial to avoid misdiagnosis and ensure timely treatment.

In conclusion, p53 staining was consistently associated with aggressive PCa and may serve as a reliable prognostic marker. High ETS2 expression correlates with delayed PSA recurrence in p53-negative tumors.

Functional assays using CRISPRi and ETS inhibitors, along with gene dependency data from DepMap, confirm ERG dependency in IKZF1 -deficient B-ALL. Our findings identify ERG as a context-specific dependency in IKZF1 -deficient B-ALL, providing a mechanistic basis for the observed mitigation of poor prognosis for IKZF1 -mutation in patients with co-occurring ERG deletions.

FOXA1 defines a major oncogenic axis in prostate cancer, distinct from TMPRSS2-ERG fusion and PROX1 induction. Class 1 and 2 FOXA1 mutations drive alternative transcriptional programs leading to therapy resistance, highlighting FOXA1 as a critical biomarker and target for chromatin-directed interventions.